Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Gens & Associates launches latest World Class RIM℠ study - the largest yet - to define & hone "industry standard" practice


News provided by

Gens & Associates

Oct 04, 2023, 08:05 ET

Share this article

Share toX

Share this article

Share toX


Stakeholders across the global Life Sciences industry & regulatory provider community are invited to play their part in cementing the ultimate approach to regulatory information management

NEWTOWN, Pa., Oct. 4, 2023 /PRNewswire-PRWeb/ -- Leading Life Science benchmarking and advisory firm Gens & Associates has launched its largest World Class RIM℠ Benchmark study to date. The 2024 global study of Life Sciences regulatory information management programs – the 6th in the firm's World-Class RIM series (which dates back to 2015) – will be the farthest reaching and most inclusive in terms of respondents. It will also be the deepest dive yet into hot topics such as structured data submission programs, advanced technology application to key regulatory processes, and regulatory digitization strategies.

The 2024 survey, which will help define and hone the industry standard for ultimate regulatory information management (RIM), is expected to attract record-breaking participation from 80-100 organizations. These will represent all corners of the Life Sciences industry, including small startups in the clinical stage, biotechs, medtech, generic, consumer, and combination product companies, as well as traditional pharma organizations.

This important new research will be the largest, broadest and deepest study we have done to date, in terms of the participants and our outreach to include more companies of different sizes and origins.

Post this

Over the last five years, Life Sciences companies across the world have collectively spent over $1.9 billion on improving regulatory information management, Gens & Associates estimates. The latest study will explore the impact of that investment, for instance in tangibly transforming organizations' regulatory intelligence and cross-function process efficiency.

As in previous years the World Class RIM research will delve into companies' evolving RIM strategies; peer performance status; investment priorities; advanced technology application; cross-functional connectivity; and organizational strategies to improve performance. It will also provide a comprehensive, up-to-date review of the software and service provider landscape.

Crucially, the Gens & Associates 2024 World Class RIM Benchmark study is co-designed with the Life Sciences industry, for the Life Sciences industry – ensuring that it asks the questions and secures the insights that matter most to companies as they finesse their own RIM strategies and investments tactically and strategically.

Seven industry survey design sessions will be conducted between October and December 2023, incorporating the feedback from 35-40 organizations. In the US the survey tour will take in Lambertville, New Jersey; Boston; Chicago; and San Francisco. European sessions include Copenhagen; Zurich; and London. For Asia-Pacific colleagues, collaborative survey design may take place virtually to maximize inclusion and convenience.

Commenting on the launch of the 2024 World Class RIM Benchmark study, Steve Gens, founder and managing partner of Gens & Associates, said: "This important new research will be the largest, broadest and deepest study we have done to date, in terms of the participants and our outreach to include more companies of different sizes and origins. Inclusivity is paramount, as the whole aim of this research program is to empower everyone to improve the performance of their regulatory information management program (and for the providers, of their products and services), by harnessing the latest leading practices and supporting tools.

"Our mission at Gens & Associates is 'Everybody Gets Better' – by which we mean everyone across the regulatory ecosystem (industry players, IT/service providers, and health authorities). That same philosophy is also at the heart of our World Class RIM Benchmark study. The more companies that are involved in the design of the study, and the more survey participants we attract, the more powerful the actionable insights that everyone can draw on."

Companies participating in the new study will gain access to this latest industry-recognized RIM research (typically running to 100+ pages) into key trends and practices; in addition to insights into their own performance position relative to their industry peers and the latest observed World Class RIM performance levels. They will also benefit from actionable insights, and a detailed view of the current status and emerging trends across the Regulatory software and service provider landscape.

There is no cost to take part in this blinded study. In addition to receiving the full results, participants will also have the opportunity to be part of a community debrief. First-time survey participants are invited to watch a short video covering Gens & Associates' benchmark history and value, the 2024 study focus, as well as research policy and rules. The link can be found on the Gens & Associate web site at https://gens-associates.com/world-class-rim-research/.

The 2024 World Class RIM Benchmark study is Gens & Associates' 43rd comprehensive research project in 17 years. The firm's most recent findings from 320 local affiliates representing 94 countries, which are about to be published, explore the evolving role of country Affiliates as part of efforts to centralize, streamline, and advance global regulatory information management.

About Gens & Associates

Founded in 2005, Gens & Associates Inc is a Life Science benchmarking and advisory firm specializing in improving client performance, developing clear and pragmatic strategic plans and implementation roadmaps, and supporting organizational transition. Gens & Associates' regulatory benchmark data is the industry standard – quoted by industry analysts, software and service providers, thought leaders, and utilized extensively by industry.

Gens & Associates' global network consists of seasoned professionals typically possessing 20+ years of experience and advanced degrees and certifications. Many are industry-recognized consultants having substantial experience in industry, government health agencies, or top-tier consulting firms. Gens' associates and partner organizations are located primarily in Europe and North America. In 2017, Gens & Associates was recognized in the PharmaVoice 100 as one of the most influential and inspiring organizations in the Life Sciences industry.

Gens & Associates' Membership Programs combines strategic performance improvement advisory service with access to Gens & Associates' private survey content and market reports through an Executive Lounge. More at www.gens-associates.com

PR Contact Carina Birt, Sarum PR [email protected] +44 (0)7970 006624

Media Contact

Steve Gens, https://gens-associates.com/, 1 267-614-0935, [email protected], Gens & Associates Inc

SOURCE Gens & Associates

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.